Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

Biointron, established in 2012 and ISO 9001:2015 certified, is a leading Contract Research Organization (CRO) specializing in antibody discovery, optimization, and expression services for biotech and pharmaceutical companies worldwide.Leveraging over a decade of experience, we have developed a high-

According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

Accelerating antibody research requires access to high-quality antibodies and proteins, efficient production timelines, and reliable partnerships. Biointron, a leading Contract Research Organization (CRO) specializing in antibody discovery, expression, and optimization, has become the preferred choi

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

The development of custom antibodies is a critical component in advancing research and therapeutic innovation. Biointron, a Contract Research Organization (CRO) specializing in antibody expression services, provides comprehensive support to biotech companies seeking reliable, scalable, and high-quality solutions for their antibody production needs.

Antibody drugs offer targeted and effective therapies for inflammatory conditions such as chronic diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. By specifically binding to pro-inflammatory cytokines or their receptors, monoclonal antibodies help modulate the immune response,

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

As antibody-drug development accelerates, ensuring consistent binding affinity, stability, and specificity is critical to improving treatment outcomes. Recent advances in antibody sequencing, artificial intelligence, and high-throughput screening have bolstered efforts to produce reliable antibody candidates more efficiently.

This month, two high-profile deals for bispecific antibodies targeting the PD-1/PD-L1 and VEGF pathways were announced. The DealsOn November 14, Merck announced its licensing agreement with LaNova Medicines for LM-299, an investigational PD-1/VEGF bispecific antibody. Merck is committing up to

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, the elderly, and immunocompromised individuals. Despite its global prevalence, there has historically been a lack of effective therapeutic options for high-risk populations.

Discover the latest insights on antibody drug reliability, addressing aggregation, impurities, and stability challenges in biomedical research for improved outcomes.